



Current Funding Opportunities — October 2016

**1) Examination of Survivorship Care Planning Efficacy and Impact (R01)**  
[\(PA-16-012\)](#)

**SPONSOR: National Cancer Institute**

**Synopsis:** The purpose of this Funding Opportunity Announcement (FOA) is to stimulate research evaluating the effect of care planning on self-management of late effects of cancer therapy; adherence to medications, cancer screening and health behavior guidelines; utilization of follow-up care; survivors' health and psychosocial outcomes. How organizational-level factors influence the implementation of care planning and its associated costs is also of interest. Specifically, the FOA aims to stimulate research that will: 1) develop and test metrics for evaluating the impact of survivorship care planning; 2) evaluate the impact of survivorship care planning on cancer survivors' morbidity, self-management and adherence to care recommendations, utilization of follow-up care; 3) evaluate effects of planning on systems outcomes, such as associated costs and impact on providers and organizations implementing the care planning; and 4) identify models and processes of care that promote effective survivorship care planning.

**2) National Cancer Institute Program Project Applications (P01)**  
[\(PAR-16-457\)](#)

**SPONSOR: National Cancer Institute**

**Synopsis:** With this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications for investigator-initiated Program Project (P01) applications. The proposed Program may address any of the broad areas of cancer research, including (but not limited to) cancer biology, cancer prevention, cancer diagnosis, cancer treatment and cancer control. Basic, translational, clinical, and/or population-based studies in all of these research areas are appropriate. Each application submitted in response to this FOA must consist of at least three research projects and an Administrative Core. The projects must share a common central theme, focus and/or overall objective.

Application Receipt/Submission Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. The first standard due date for this FOA is January

25, 2017. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

**3) Translational Research Program: Leukemia and Lymphoma, Familial Platelet Disease (FPD) / RUNX1 and Myeloma**

<http://www.lls.org/research/translational-research-program>

**SPONSOR: Leukemia & Lymphoma Society (LLS)**

**Synopsis:** Applications are sought proposing novel approaches to the prevention, diagnosis or treatment of hematological malignancies and related pre-malignant conditions. Proposals should be based on molecular, cellular or integrated systems findings and be conceptually innovative. The application should have a clear plan for the clinical translation of the studies proposed and the results expected. This feature will be an important consideration of the review process.